Rafeah AlamRafeah graduated from University College London in 2010 with a BSc in Pharmacology. This was followed by a Master’s in Drug Discovery Skills at Kings College London in 2011. As part of her MSc she spent 5 months at AstraZeneca where she worked on assessing the impact of acute cytotoxic treatment on signalling pathways in human tumour models. Following her MSc degree, she spent 2 years working at UCB as a Research Assistant exploring the in vivo potential of some of the therapeutics focused on autoimmune diseases. Her current project as a PhD student at the Babraham Institute involves investigating the effect of overactive p110δ activity on T cell function in a model of a newly discovered primary immunodeficiency ‘’Activated PI3Kδ syndrome’’.
Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4(+) T Cell Differentiation via PI3K p110δ-Akt-Mediated Signals.
Mauro C, Smith J, Cucchi D
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Okkenhaug K, Graupera M, Vanhaesebroeck B
Eil R, Vodnala SK, Clever D
537 1476-4687:539-543 (2016)
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI, Chandra A, Bacon CM
The Journal of allergy and clinical immunology
Roychoudhuri R, Clever D, Li P
Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.
Barbera Betancourt A, Emery JL, Recino A
11 1932-6203:e0146516 (2016)
PI3Kδ promotes CD4(+) T cell interactions with antigen presenting cells by increasing LFA-1 binding to ICAM-1.
Garçon F, Okkenhaug K
Immunology and cell biology
Roychoudhuri R, Eil RL, Clever D
The Journal of clinical investigation
Okkenhaug K, Roychoudhuri R
8 1937-9145:pe3 (2015)
Okkenhaug K, Burger JA
Current topics in microbiology and immunology
393 0070-217X:123-42 (2016)
Sauer K, Okkenhaug K
Frontiers in immunology
6 1664-3224:410 (2015)